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A 59-year-old white man with a history of recurrent pleural effusions,
coal worker's pneumoconiosis, and a positive PPD presented with hemop-
tysis beginning on the morning of admission. The patient had coughed up
small amounts of dark blood totaling approximately 4 ounces; although
this was his first episode of hemoptysis, he had experienced epistaxis
approximately once weekly in the previous year. The patient was married,
had smoked one pack of cigarettes/day for 30 years, but had quit four years
ago. He occasionally drank alcoholic beverages, and he was a retired coal
miner who had worked directly in the mines. He denied fever, chills, night
sweats, weight loss, decreased appetite, nausea, vomiting, shortness of
breath, or cough. The patient complained of a transient nonspecific rash in
the previous weeks that had resolved.
The medical history was notable for a recurrent left-sided pleural
effusion 5 years previously with a negative workup for collagen-vascular
disease, malignancy, and infection. He had had nephrotic-range protein-
uria four years prior to admission; renal biopsy then demonstrated focal
segmental glomeruloselerosis. Treatment with an angiotensin-converting-
enzyme inhibitor reduced the proteinuria to below 400 mg/24 hours. The
family history was negative.
Physical examination revealed a well-appearing white man in no
apparent distress. His temperature was 37°C; respirations, 20/mm; pulse,
80 beats/mm; and blood pressure, 120/60 mm Hg. The head, eyes, ears,
nose, and throat were normal, as was the neck. The lungs were clear to
auscultation. Cardiac examination was unremarkable. His abdomen was
soft, nontender, and his extremities showed no evidence of clubbing,
cyanosis, or edema. Neurologic examination was normal.
Laboratory evaluation revealed a white blood cell count of 9700/mm3;
hematocrit, 41%; and platelets, 192,000/mm3. Blood urea nitrogen (BUN)
was 40 mgJdl and serum creatinine concentration 2.3 mg/dl; two months
ago, the BUN was 25 mg/dl and the serum ereatinine, 1.4 mg/dl. Total
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serum protein and albumin were normal. Blood gases obtained while the
patient was breathing room air were: pH, 7.37; PaCO2, 33 mm Hg; and
Pa02, 80 mm Hg. A chest radiograph revealed a new right upper lobe
infiltrate (Fig. 1). Urinalysis showed 3+ protein, large blood, dysmorphic
red blood cells, granular casts, and red cell casts.
The patient was admitted to the hospital for further workup. He
underwent bronchoscopy with broneho-alveolar lavage (BAL) as well as
ventilation/perfusion scan. Culture and cytologic examinations of the BAL
fluid were negative, and the sean was interpreted as a low probability for
pulmonary embolus. The assay for anti-neutrophil eytoplasmic antibody
(ANCA) was positive at 1:1280 with a perinuclear pattern of fluorescence.
Antibodies to the glomerular basement membrane (GBM) were negative
by indirect fluorescence assay. Renal biopsy contained 13 glomeruli, 5 of
which were globally sclerotic and obsolescent. The remaining 8 had
varying degrees of hypercellularity and segmental sclerosis; two demon-
strated epithelial crescents (Fig. 2). The interstitium showed a moderate
amount of tubular atrophy and fibrosis with a mild mononuclear cell
infiltrate. No vasculitis was seen. Immunofluorescent examination re-
vealed IgG in a moderately intense linear pattern along the GBM and a
similar pattern of staining for kappa and lambda light chains (Fig. 3). C3
was found only in the mesangium without GBM staining. Fibrin was
present in glomerular crescents (Fig. 3). Electron microscopy revealed no
immune deposits. Anti-GBM assay by ELISA was positive against the
recombinant rs3(IV) NC1 domain.
The patient was treated with prednisone, 70 mg/day, and 200 mg daily
of eyclophosphamide, which was tapered over six months. Over a period of
one month, the patient's serum creatinine concentration returned to 1.4
mg/dl with a BUN of 36 mg/dl. At that time, the urinary sediment showed
only an occasional red cell with no red cell casts.
Discussion
DR. W. KUNE BOLTON (Chief Division of Nephrology, and
Professor of Medicine, University of Virginia Health Sciences Center,
Charlottesville, Virginia): The present case was selected to illus-
trate some of the typical features seen with Goodpasture's
syndrome (GPS), as well as some of the atypical features that are
of major clinical importance to the practicing nephrologist. This
patient also illustrates some new ideas in diagnosis, prognosis, and
therapy. The term "GPS" is an eponym derived from a report in
1919 by Ernest Goodpasture, who described the clinical syndrome
of pulmonary hemorrhage associated with influenza infection and
the histologic finding of acute creseentic glomerulonephritis (GN)
[1, 21. We do not, as a matter of fact, know that the patients
described by Goodpasture had anti-GBM disease. Over the years,
the terminology has been used in different ways by different
individuals, some including all causes of pulmonary hemorrhage
with renal dysfunction as GPS [3]. Others limited the term GPS to
patients with pulmonary hemorrhage associated with anti-GBM
antibodies, as opposed to GN with anti-GBM antibodies but
without pulmonary hemorrhage [4]. Yet others espouse the
concept of anti-type-TV collagen disease rather than GPS [5].
Although most of the antibody activity is directed to the
1753
Editors
JORDAN J. COHEN
JOHN T. HARRINGTON
NIc0LAOs E. MADIAS
Managing Editor
CHERYL J. ZUSMAN
Tufts University School of Medicine
Case presentation
1754 Nephrology Fonim: Goodpasture r syndrome
Fig. 1. Chest roentgenogram showing right upper
lobe infiltrate which appeared coincident with
hemoptysis.
a3(IV)NCI domain of type-IV collagen, antibody to other chains
and other constituents of the GBM can occur [6—8]. Indeed,
studies both in humans and animal models demonstrate that many
different anti-GBM antibody specificities are found clinically, and
that although all these antibodies fix to the GBM, the resultant
clinical phenotypes can be quite different. Since the target anti-
gen(s) (GBM) appear to be the same regardless of the clinical
presentation, and anti-GBM-associated clinical findings can range
from normal renal function with asymptomatic GBM deposits
without pulmonary symptoms, to pulmonary hemorrhage with or
without GN, to GN with or without pulmonary involvement, it
seems impractical to subdivide thc clinical presentation based only
on the presence or absence of pulmonary hemorrhage. I therefore
consider any patient with anti-GBM antibodies deposited in tissue
as having GP disease, and patients with GP disease and GN or
hemoptysis or both as having GP syndrome. Thus the antibodies
and target epitopes are the common link among the various
clinical presentations, and it is the environmental and secondary
effector systems that determine the clinical presentation. In this
context, patients who have had renal transplants and recurrent
anti-GBM antibody on the basement membrane without pulmo-
nary hemorrhage and without GN are still classified as part of the
spectrum of GP disease, as are symptomatic and asymptomatic
allografted patients with Alport's syndrome who have de-novo
anti-GBM antibody deposits. It seems likely that, as we gain a
better understanding of the pathogenesis of this disease, we will
be able to define why the clinical spectrum is so variable and will
be able to develop more rational and specific forms of therapy for
GPS.
Epidemiology and clinical manifestations
Goodpasture's syndrome is uncommon, having an incidence of
approximately 0.1 cases per million population. In our experience,
it accounts for approximately 1% to 2% of renal biopsy specimens
[9]. The distribution by gender is approximately equal, with a very
slight preponderance of males to females. The age at presentation
can range from the first to the ninth decade, so the commonly held
concept that this is a disease of young males is of little clinical
practicality. There is, however, a bimodal distribution, with a
greater number of individuals presenting around age 30 and a
second peak at around age 60 [10]. This latter group has a slighter
greater tendency for female distribution and GN rather than
pulmonary hemorrhage, but these tendencies are of little clinical
importance. The disease is more common in whites than in
African-Americans and may be more common in certain other
racial groups, such as the Maoris in New Zealand [111. Goodpas-
ture's syndrome can present year round, but its incidence appears
to increase in the spring and early summer; some localized
outbreaks have been associated with infection. In our experience,
approximately one-half to three-quarters of patients have some
type of pulmonary presentation, such as cough, or upper respira-
tory tract infection, plus fever, rash, myalgia, malaise, headaches,
weight loss, or other vague signs and symptoms.
In patients with renal involvement, an active urinary sediment
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Fig. 2. Light microscopic photograph showing
Jical segmental glomerular sclerosis. A, first
biopsy; B, a glomerulus with a crescent (arrow),
second biopsy.
with dysmorphic red cells and red cell casts is extremely common.
If urinary findings are not present, one should consider other
diseases. Proteinuria usually is present, hut not in the ncphrotic
range, although an occasional patient will have heavy proteinuria.
Significant hypertension is usually not a feature of the disease, but
mild increases in blood pressure consistent with age do occur.
Ultrasonography reveals normal-sized kidneys with normal echo-
texture and without anatomic abnormality. Renal function can
range from normal to rapidly decreasing over a few weeks or
months [9, 12—14]. We define rapidly progressive GM (RPGN),
frequently seen in GPS, as a halving of GFR or doubling of serum
crcatinine within three months or less [91.
In patients who also have pulmonary involvement, the presen-
tation is nonspecific; GPS is but one of many causes of pulmonary
hemorrhage (Table 1). These causes include vasculitis (including
most importantly, microscopic polyarteritis nodosa, Wegener's
granulomatosis, and Churg-Strauss vasculitis), certain collagen-
vascular diseases, and a variety of different types of GN. However,
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Table 1. Renal disease with pulmonary hemorrhage
Glomerulonephritis
Goodpasture's syndrome
Immune-complex glomeruloncphritis
Acute silicoprotcinosis
Glomerulonephritis with CHF
D-penicillamine toxicity, trimellitic anhydride toxicity
Vasculitis
Polyarteritis nodosa
Microscopic polyarteritis nodosa
Wegener's granulomatosis
Henoch-Schönlein purpura
Mixed IgG-IgM cryoglobulinemia
Churg-Strauss allergic vasculitis
Lymphoid granulomatosis
Necrotizing sarcoid granulomatosis
Hypersensitivity
Behcet syndrome
Hughes-Stovcn syndrome
Giant cell arteritis
Hypocomplementemic urticaria
Takayasu's arteritis
Collagen vascular disease
Systemic lupus erythematosus
Progressive systemic sclerosis
Rheumatoid arthritis
Cardiovascular disease
Advanced uremia with superimposed CHF
Mitral stenosis
Pulmonary embolism with infarction and underlying renal vein
thrombosis
Infection
Legionnaire's disease
Necrotizing pneumonitis
Bronchitis
Tuberculosis
Fungus
Lung abscess
Bronchiectasis
Malignancy with associated glomerulopathy
Blood dyscrasias
Thrombotic thrombocytopenic purpura
Hemolytie-uremic syndrome
Idiopathic hemosiderosis
Fig. 3. Immunofluorescence microscopy illustrating (A) linear deposits of
IgG along GBM and (B) fibrin within a crescent.
the differential diagnosis must include infection, malignancy, and
any cause of pulmonary hemorrhage with decreased renal func-
tion, as can occur with various antibiotics and unrelated acute
renal failure. Pulmonary hemorrhage can precede the develop-
ment of GN by several years, or it can develop after renal disease
is manifest. The intensity of pulmonary hemorrhage provides few
clues to the presence of GPS and can range from blood-streaked
sputum to massive fatal pulmonary hemorrhage. Quite clearly,
temporal relationships exist between hemoptysis and environmen-
tal exposure, including various hydrocarbons, especially cigarette
smoking, and episodes of infection [15, 16]. Patients often com-
plain of shortness of breath and cough, but usually not chest pain
or pleurisy, as occurs with pulmonary embolism.
Examination of the sputum can demonstrate hemosiderin-
containing macrophages, a nonspecific finding indicating pulmo-
nary hemorrhage; chest radiographs reveal variable results. Alve-
olar infiltrates spreading out from the hilum are common, but
nodular densities and isolated segmental infiltrates do occur, as
seen in today's patient. Pulmonary function can be decreased, and
episodes of pulmonary hemorrhage are associated with increased
uptake of carbon monoxide, which can be used as a test of
pulmonary hemorrhage and to document intercurrent episodes of
pulmonary hemorrhage [17]. Increased uptake occurs because of
binding of carbon monoxide to extravasated blood within the lung
and formation of carboxyhemoglobin in alveoli.
Laboratory findings
The sine qua non for the diagnosis of GPS is demonstration of
bound anti-GBM antibodies in the glomeruli of the kidneys. This
finding usually is reflected by the presence of circulating anti-
GBM antibodies, most commonly of the IgG class, although
occasionally IgA or 1gM [18]. The detection method for this
common laboratory test is an extremely important consideration.
Although circulating anti-GBM antibodies are present in more
than 90% of patients with anti-GBM disease, indirect fluorescent
assays using kidneys from various species as substrate, including
monkey kidney, can be falsely negative in 10% of cases or more.
In the present case, this method was used because it is less
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Anti-GBM disease
Goodpasture's syndrome
Idiopathic RPGN
Membranous nephropathy with secondary anti-GBM disease
ANCA + vaseulitis
Non-anti-GBM disease
Diabetic nephropathy
Renal allograft cx-vivo perfusion
Focal sclerosis (rare)
Polyarteritis
Post-infectious glomerulonephritis (rare)
Minimal-change disease (rare)
Ankylosing_spondylitis_(rare) -
expensive than are radioimmunoassays (RIA) and ELISAs, which
are more specific and have less than 5% false-negative rates. On
the other hand, there are few false-positive results with these
assays. Indirect fluorescence tests, as well as RIA and ELISA, are
falsely positive in probably 1% or less of positive tests. False-
positive tests can arise from antibodies directed against other
constituents of type-IV collagen, from inexperience in interpreta-
tion of indirect fluorescence, and from lack of proper controls.
When pulmonaiy hemorrhage, GN, and a negative RIA or ELISA
assay are found, the chances of GPS are remote.
In my opinion, the diagnosis must be made on the basis of renal
histologic examination unless biopsy is contraindicated. We per-
form a renal biopsy on an emergency basis in any patient who
might have GPS, regardless of the presence or absence of
anti-GBM antibodies in the circulation. The rationale for this
aggressive diagnostic approach involves the need for assessing the
degree of crescent involvement and the amount of sclerosis and
fibrosis at presentation, and to ascertain whether another disease
process is present [19]. Time is critical, because prognosis and
response to therapy are closely tied to duration of disease and
level of renal function prior to diagnosis and treatment. The
presence of linear GBM deposits does not necessarily indicate
GPS (Table 2), and determination of whether antibodies in the
circulation or on the GBM in vivo are specific for GBM is a
necessary confirmation for the diagnosis of GPS. If circulating
anti-GBM antibody is present, this is sufficient; if not, micro-
elution of renal tissue sections is necessary. Specific antibodies
eluted from glomeruli by indirect fluorescence fix to normal
human GBM, whereas antibodies in non-anti-GBM disease asso-
ciated with linear deposits do not fix to normal human GBM.
In summary, the differential diagnosis of GPS encompasses the
spectrum of any type of GN associated with any degree or cause
of pulmonary hemorrhage. The broader definition of GPS utilized
in this discussion makes a renal biopsy imperative in virtually all
patients with any renal manifestations, including an active urinary
sediment or abnormal urinary protein, to clarify the underlying
pathology. The pathologic diagnosis has major importance in the
choice of appropriate therapy.
IVatural course and prognosis
The clinical course of untreated, and even treated, GPS is
bleak; this disease generally is associated with an extremely poor
prognosis [10, 20, 21]. When we reviewed the natural course and
prognosis of GPS in the mid-1980s, 89% of patients reported in
the literature who were treated with various types of immunosup-
Vaseulitis
Wegener's granulomatosis
Churg-Strauss allergic vasculitis
Microscopic PAN
Anti-GBM disease
Crohn's disease
Ulcerative colitis
Felty's syndrome
Sjogren's syndrome
Polymyositis
Systemic lupus erythematosus
Henoch-Schdnlein purpura
Rheumatoid arthritis
Hemodialysis
Chronic liver disease
HIV infection
Other acute/chronic infection
pressive therapy, but not pulse methylprednisolone or plasma
exchange, progressed to death or dialysis; only 10% experienced
some type of improvement [9]. The observation that anti-GBM
antibodies appear to cause the disease led to the use of plasma
exchange as the appropriate therapeutic modality [22, 231. With
this type of treatment, approximately 50% of patients improved.
However, patients with oligoanuria and those on dialysis uni-
formly fail to respond to plasma exchange, pulse methyipred-
nisolone, or other therapy [9, 19, 23, 24]. Of note are rare reports
of patients with GPS who apparently recovered spontaneously
even after acute renal failure and the requirement for dialysis, and
those in whom withdrawal of the offending agent, such as hair
spray, was associated with recovery [25—27]. In general, however,
the consensus has been that the prognosis is extremely poor, but
perhaps improving because the defined spectrum of the disease is
increasing (thus, embracing less ill patients), and because both
specific and general medical therapy have improved. We should
remember, however, that the grim figures on prognosis refer to
GPS patients with the clinical presentation of RPGN.
Other factors also are important in the overall prognosis of
GPS. A clear genetic influence exists. Patients who carry an
HLA-DR W2, especially with HLA-B7, appear to have a more
malignant course of ON [23, 281. A high degree of crescent
formation (that is, more than 50%), the presence of tubulointer-
stitial disease with fibrosis, scarring, and glomerulosclerosis all
bode ill for the patient [19, 29]. In patients who have a serum
ereatinine of 6 mg/dl, oliguria, or anuria, and in those requiring
dialysis, response to therapy is extremely poor and recovery rare.
ANCA and anti-GBM antibodies
Today's patient had circulating ANCA in a perinuelear pattern
(pANCA), which is associated with antibodies to myeloperoxi-
dase. Although numerous diseases are associated with ANCA
(Table 3), we usually associate its presence with vasculitic syn-
dromes [301. We used to think that coexistent GPS and vasculitis
were rare, and isolated reports of this association were considered
interesting oddities [31, 32]. In 1989, however, O'Donoghue et al
reported three patients with ANCA-positive serum and anti-GBM
disease [33]. Since that time a number of additional patients have
been described, yielding a surprisingly high prevalence of ANCA
with GPS [34—36]. Approximately 30% of patients with circulating
anti-GBM antibodies will have circulating ANCA at some time
Table 2. Linear GBM deposits Table 3. Positive ANCA-associated conditions
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during the course of the disease. The ANCA can be positive prior
to or after the development of anti-GBM disease. In patients with
anti-GBM disease, the pattern for thc ANCA is perinuclear in at
least three-fourths of the patients and cytoplasmic in the other
one-quarter. The clinical course of disease in patients with
anti-GBM disease and a positive ANCA appears to be somewhat
different than that in those with pure anti-GBM disease. First,
only about one-half the "double-positive" patients require dialy-
sis. In contradistinction to the scenario with GPS, a substantial
number of ANCA-positive patients have recovered sufficient renal
function to stop dialysis, although the exact percentage is not clear
[34, 351; it might be as high as 30% to 50% judging from the small
series that are available. Many ANCA-positive patients also have
other vague systemic findings, including rash, fever, and myalgia,
which are more suggestive of a vasculitie process than pure
anti-GBM disease, although such findings can occur with GPS.
Finally, there appears to be an inverse correlation between
anti-GBM titers, ANCA titers, and disease course; that is, patients
who have higher ANCA titers and lower anti-GBM titers tend to
have a course that is more suggestive of vasculitis and respond to
therapy and even recover from dialysis; those with the highest
anti-GBM titers pursue a more devastating course without return
of renal function. Another clinical feature of "double-positive"
patients is the tendency for frequent relapses, seldom seen in
patients with pure anti-GBM disease. However, information
regarding this clinical entity is scant at present. Further studies are
needed to clarify the interrelationship between anti-GBM and
ANCA, and to determine what therapy is most appropriate and
what factors determine the response to therapy. Because ANCA
is a relatively new laboratory test, it is not known how many
patients reported in the literature over the last several decades
with anti-GBM disease had concomitant ANCA positivity and
how that affected the results of previous studies.
Pathogenesis
Understanding the pathogenesis of a disease is of paramount
importance for developing specific therapy. The classic studies by
Lerner, Glassock, and Dixon nearly 30 years ago were among the
first demonstrations of a GN in which the pathogenesis was known
[37]. In those studies, nephritic kidneys obtained from patients
with GPS were acid-eluted and the eluted antibody purified. The
antibody then was injected intravenously into unilaterally ne-
phrectomized monkeys. Microscopic examination of the GBM
revealed intense staining for human IgG associated with fulmi-
nant GN, pulmonary hemorrhage, and progression to renal failure
with proteinuria. The recent observations that GBM, lung, cho-
roid plexus, and basement membranes within the eye contain
additional collagen chains other than the a1 and a2 typically found
in type IV collagen, and documentation that most of the circulat-
ing antibodies in patients with GPS are directed to the a3
non-cotlagenous (NCI) domain of type IV collagen, has added
greatly to our understanding of the pathogenesis of GPS [7, 8, 38,
391. Although controversial, much evidence suggests that the
circulating antibodies in patients with GPS are targeted mainly to
the a3NC1 domain, with much of that reactivity to the last 36
amino acids of the chain; these have been termed "Goodpasture's
epitope" [40]. Further evidence of the specificity of these antibod-
ies for this domain has been derived from the studies by Neilson
and coworkers, who expressed recombinant proteins for the first
five NC1 domains of type IV collagen and showed that the only
one with significant binding with Goodpasture's sera was a3 [41].
Other laboratories have reported that Goodpasture's sera, while
showing broad reactivity to various components of GBM, includ-
ing other NC1 domains, nonetheless have most reactivity to the
a3NCI domain [6—81.
As with other autoimmune diseases, patients have a strong
susceptibility based on genetic background and, as I noted, certain
HLA antigens are clearly associated with susceptibility to GPS
and possibly to a worse phenotype. This association is similar to
the demonstration in various animal species of strain and species
differences in susceptibility to disease [42]. Much evidence sup-
ports the concept that insult to the basement membrane or
cross-reactivity with exogenous epitopes can initiate the process of
autoimmunity resulting in the phenotype of GPS (Table 4).
Different initiating events, such as infection, exposure to toxins,
renal injury (including underlying glomerulopathy, as in today's
patient), ischemia, membranous nephropathy, and various types
of neoplasia could expose cryptic antigens by damaging the GBM.
In addition, urine contains antigens that conceivably could result
in an autoimmune response if they gained access to the circula-
tion. Finally, the model of most interest is that of Alport's familial
nephritis. These patients' GBMs are nonreactive with Goodpas-
ture's sera as opposed to normal GBM, and they lack the epitope
to which Goodpasture's sera react [43, 44]. Many different abnor-
malities of a3(IV) collagen, which have been associated with
Alport's syndrome, might result in incorrect assembly of the
a3NCI domain in the GBM, thus accounting for the lack of the
Goodpasture's epitope. Transplantation in patients who have
end-stage renal disease from Alport's syndrome has been associ-
ated with the development of circulating anti-GBM antibodies
and their deposition in the graft, resulting in loss of the graft from
anti-GBM disease in a small number of cases [45—48]. Patients
who have this latter syndrome appear to be those most likely to be
reported in the literature, as the actual occurrence with conse-
quent graft loss may be small. In a combined series of 75 patients
with Alport's disease who received renal transplants, 8 developed
anti-GBM antibodies, and 2 patients lost their grafts [45—47].
Retransplantation in these 2 patients produced good graft sur-
vival, however. Thus, it seems obvious that some patients do
indeed develop de-novo anti-GBM disease in the normal allograft
in the setting of Alport's syndrome, but this is relatively uncom-
mon. Whether these patients were of a nonsusceptible MHC type
or whether other factors were involved is not clear. Patients with
GPS have an exuberant cellular infiltrate with macrophages and
T-cells and an intense secondary effector response, which appears
responsible for the final phenotypic expression [discussed in detail
in Refs. 23, 49—53].
Table 4. Events associated with the induction of anti-GBM disease
in humans
Infections
Toxin exposure
Renal injury
Neoplasia
Neoantigens
Endogenous antigens
Influenza
Bacterial endocarditis
Hydrocarbons, tobacco, drugs
Ischemia, membranous ncphropathy
Lymphomas, adenomas
Alport's syndrome
GBM
Lung
Urine
Choroid plexus
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Experimental studies show that GBM contains antigens that
can induce experimental autoimmune GN in several species,
including sheep, goats, rats, rabbits, and mice [54—58]. The
nephritogenic component that causes the proliferative GN ap-
pears to be present in dimers containing a3, a4, and a5, and not in
those dimers containing a1 and a2 [57]. Recent studies from
Kalluri and colleagues show that dimers of NC1 type IV collagen
containing mostly a3 but also some components of a1, a2 and a4
can induce GN in rabbits and mice [57, 58]. The work from our
own laboratory and that of Sado shows that GBM collagen
induces a model that appears to parallel GPS in every respect,
complete with proteinuria, proliferative necrotizing GN with
crescents, circulating and bound anti-GBM antibodies, and pul-
monary hemorrhage [55, 56, 59, 601.
It remains to be seen whether the nephritogenic antigen
involved in GPS is the same as that in experimental models of
GPS. Although a3NCI-enriched dimers produce disease, and type
IV collagen lacking a3NC1 does not, immunization of rats with
Goodpasture's epitope is likewise unproductive of disease [57—59,
61]. Whether this latter outcome results from lack of conforma-
tional changes that are pathogenic, whether other modifications
of the molecule are required for nephritogenicity, or whether
different effector mechanisms are involved with synthetic peptides
rather than with native protein are among possibilities that remain
to be evaluated. It is clear that patients with GPS have many
different circulating antibodies to a variety of components of
basement membrane, and that these antibodies can react with
different peptides along the a3NCI chain. If the true nephrito-
genic peptides can be identified, then direct intervention in GPS
is feasible. However, patients and animals alike can demonstrate
circulating and bound anti-GBM antibody without disease, and
patients who had GPS originally can receive transplants without
developing GPS or even GP disease [62, 63]. Why these differ-
ences occur and what accounts for them are intriguing questions,
the answers to which will further refine our ability to model
specific therapies for this devastating clinical syndrome.
Treatment
Pulmonary hemorrhage associated with GPS usually responds
rapidly to pulse methylprednisolone or to plasma exchange [9, 23,
64]. In some patients, neither modality is of benefit; we have had
a few patients with intractable pulmonary hemorrhage who have
died because plasma exchange, pulse methyiprednisolone, and
cytotoxic therapy all were ineffective.
As I said earlier, conventional treatment—defined as prednisone
and other types of immunosuppression in standard doses—has
produced little beneficial effect. The presence of circulating
anti-GBM antibodies has served as an obvious rationale for
removal of these antibodies by plasmapheresis or immunoglobu-
lin-adsorbent columns. Although the literature contains limited
information about patients who have anti-GBM disease with
normal kidneys or minimal renal disease, it seem obvious that this
group of patients will have a good prognosis with either no
therapy, withdrawal of the offending agent, or standard immuno-
suppressive therapy [12, 13, 261. In the setting of RPGN or active
crescentic involvement on renal biopsy, however, aggressive ther-
apy is required in those patients with the potential for benefit. In
contrast, patients who have the poor prognostic findings I men-
tioned are unlikely to respond and should be spared the risks of
aggressive therapy.
I would like to address the issue of plasmapheresis. The largest
series to date is that from Lockwood et al, who have treated more
than 100 patients with anti-GBM disease, most of whom have
been treated with plasma exchange and immunosuppression [10,
23, 24, 651. Six of seven patients with normal renal function who
were treated all improved, and one patient with normal renal
function improved without treatment. Three-fourths of 20 pa-
tients with serum creatinine levels of  7 mgldl improved with
plasma exchange, but only one of 12 with creatinine levels > 7
mg/dl showed improvement. No improvement was observed in
any of the 58 patients who were on dialysis.
Plasma exchange effectively removes circulating antibodies
directed to GBM [22, 64]. Standard therapy consists of 14
exchanges of 4 liters each over two weeks, combined with pred-
nisone and immunosuppressive drugs such as cyclophosphamide
or azathioprine. This approach diminishes circulating antibody
levels without rebound after cessation of plasma exchange as long
as immunosuppressive therapy is continued. However, there is no
good correlation between circulating antibodies at the time of
presentation and the histologic severity of GN, nor does a good
correlation exist between a decrease in antibody titers and re-
sponse to therapy in the patients who do not require dialysis [22,
66]. Only one prospective randomized controlled study has been
accomplished. In this study, Johnson and coworkers compared the
effects of therapy with pulse methyiprednisolone immunosuppres-
sion alone to immunosuppression combined with plasma ex-
change (Fig. 4) [64]. Although antibody levels were reduced to a
much greater extent, as one would expect with plasma exchange,
there was no significant difference in the clinical outcome between
the two groups. Analysis of clinicopathologic findings at study
entry suggested that the percentage of crescents on initial renal
biopsy and the entry serum creatinine concentration correlated
better with outcome than did the type of therapy utilized. The
authors noted that the patients with a lower percentage of
crescent formation and well-preserved renal function did better
with either type of treatment than did patients with severe
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crescentic involvement and impaired GFR. Although this is the
only prospective randomized trial that has been done, it had only
17 patients. Our own experience and that of others has suggested
that patients with mild anti-GBM disease may well respond to
therapies other than plasma exchange [52, 67]. Figure 5 graphi-
cally displays the results of four series in which adequate infor-
mation allowed assessment in individual patients of the impact of
serum creatinine and percentage of crescent involvement [19, 64,
66, 68]. Patients were treated with plasma exchange, pulse meth-
ylprednisolone, or conventional therapy (defined as no therapy or
any type of immunosuppression other than plasma exchange or
pulse methylprednisolone) [91. Patients treated with plasma ex-
change received variable numbers of exchanges but also received
prednisone and cyclophosphamide. The individual patients from
the four series are differentiated by symbols. As Figure 5 illus-
trates, patients with anti-GBM disease generally segregate at
entry into the medical system into those who have a serum
creatinine of  5 mg/dl and < 50% crescents or those who have
a greater involvement of glomeruli, with > 50% crescents and a
serum creatinine > 5 mgldl. In the former group, 78% of patients
treated with conventional therapy or pulse methylprednisolone
were stable or improved (11/14) compared with 11 patients
Non-Px Px
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treated with plasma exchange, all of whom were stable or im-
proved. Conversely, in the patients with serum creatinine levels of
> 5 mg/dl or > 50% crescents, none of the 36 patients treated
with any type of immunosuppression alone showed any improve-
ment, nor did any of the 5 patients treated with plasma exchange.
These findings are consistent with the large series from Lockwood
in which these latter types of patients showed no response [231.
While the recommendation always has been that patients with
anti-GBM disease should be treated first and foremost with
plasma exchange, several issues need to be considered. Patients
with lesser degrees of crescentic involvement and with less
advanced renal failure appear to do very well without plasma
exchange. In patients who have GPS and who receive transplants
[62, 63, 69], anti-GBM deposits recurred in approximately one-
half of them but only one-third of the patients with anti-GBM
antibodies lost their transplants because of recurrent disease. All
those patients were, of course, receiving immunosuppressive
therapy for their allograft and were temporally distant from the
original initiating process. In addition, in patients with Alport's
syndrome who are known to have an increased risk of developing
anti-GBM disease, the de-novo development of anti-GBM disease
associated with linear deposits along the GBM on neo-antigens in
the allograft is uncommonly associated with loss of the transplant
[45—47]. Finally, plasma exchange removes circulating antibodies,
which do not correlate well with the clinical course, but it also
induces a state of immunosuppression, causes "decomplementa-
tion," and decreases fibrinogenic products. Substances that might
have immunoregulatory activities, such as anti-idiotypic antibod-
ies, are removed as well. We have in fact seen several patients with
minimal renal dysfunction who were treated with plasma ex-
change and who appeared to have an acceleration of their disease
that resulted in an eventual need for dialysis and transplantation.
These observations suggest that the question of appropriate
therapy for anti-GBM disease is still not entirely settled.
Nonetheless, it is necessary to have a therapeutic stratagem for
approaching the patient with GPS in the clinic. Table 5describes
our therapeutic protocols, and the algorithm in Figure 6 presents
our approach to the diagnosis and therapy of GPS. The corner-
stones in decision-making are the serum ANCA studies, the renal
biopsy, the anti-GBM assay, and the patient's renal function. In
ANCA-negative patients with serum creatinine levels  6 mg/dl
and  50% crescents, we generally use plasma exchange and
immunosuppression. For patients with > 50% crescents and > 6
mgldl serum creatinine, oligoanuria, or those on dialysis, we treat
pulmonary hemorrhage but utilize only a short course of plasma
exchange and immunosuppression or none at all. If the ANCA is
positive, we treat for vasculitis with or without plasma exchange.
For non-dialysis-dependent patients with high-titer anti-GBM
antibodies, we use plasma exchange and immunosuppression.
Although plasma exchange appears of no benefit for dialysis-
dependent patients with GPS, there is evidence that it is useful if
vasculitis is the cause of dialysis dependence [701. Therefore we
use plasma exchange and immunosuppression for dialysis-depen-
dent, "double-positive" patients. For low-titer anti-GBM/ANCA-
positive patients, we lean more toward using therapy directed
against vasculitis, that is, pulse methylprednisolone or oral pred-
nisone and cyclophosphamide, although others use intravenous
cyclophosphamide [71, 72]. We might be swayed to add plasma-
pheresis if an RPGN course or a highly active histologic lesion
were present. When plasma exchange is used, one could make an
Table 5. Therapeutic protocols
A. Pulse methylprednisolone
Volume repletion ascertained
No diuretics 3 hours before pulse or 24 hours after
30 mg/kg methylprednisolone given IV over 20 minutes every
other day for 3 doses
Single dose not to exceed 3 g
Monitor blood pressure during and 4 hours after infusion
B. Oral prednisone, given every other day
Dose" (mg/kg) Duration/months of therapy'
2.0 0.5
1.75 1.0
1.50 3.0
1.25 6.0
1.00 6.0
0.75 6.0
0.50 6.0
0.25 6.0
0.125 12.0
0.0625 12.0
C. Cyclophosphamide
2.0 mg/kg daily for 3 months
1.5 mg/kg daily for 3 months
1.0 mg/kg daily for 3 months
0.5 mg/kg daily for 3 months
Decrease dose 50% for Ccr 10 mg/mm"
Hold dose if WBC 3500/mm3, or platelets 100,000/mm3
D. Plasma exchange
4 liter exchanges 5/7 days or every other day X 14 exchanges
minimum
Replacement with 5% normal human serum albumin
Fresh-frozen plasma if bleeding problems
Always be certain cyclophosphamide is used when patients receive
plasma exchange (immunoglobulin rebound suppression)
-
a Patients
 60 years of age should receive 75% of oral prednisone dose
on alternate days; for very obese patients, use ideal body weight.
h If full remission of proteinuria, normal function for one month,
decrease to next dose step.
Ccr = creatinine clearance.
argument for plasma replacement rather than albumin in patients
with ANCA, because plasma can have beneficial effects even in
vasculitic patients refractory to standard vasculitis therapy [73]. In
all cases, treatment is individualized by clinical judgment in an
attempt to provide the most effective treatment while not putting
the patient at undue risk from therapy. These considerations
tempered the treatment decision for the patient presented here.
Many types of therapy not discussed here have been tried in
GPS without success. Data from experimental animals suggest
that a variety of new agents may be beneficial in GPS. These
include IL-i receptor antagonists, TNFa receptor protein, anti-
bodies to various cell-surface adhesion molecules, deoxyspergua-
un, and immunoregulating proteins such as CTLA4-Ig [74—77].
Removal of anti-GBM antibodies by immunosorbent columns has
yielded no benefit [78]. Perhaps one of the most exciting potential
therapies is the use of immunosorbent chromatography using the
Goodpasture epitope to remove circulating antibodies. Prelimi-
nary evidence from Boutaud et al demonstrates that anti-GBM
antibodies can be absorbed from the serum of patients with GPS
using recombinant a3(IV) NC1 domain [79].
Finally, as in the case of the anti-GBM assay, additional
important considerations these days include the cost of therapy.
At our institution, a 14-day course of plasma exchange is approx-
imately $34,000 plus the cost of hospitalization. The cost of pulse
History & physical
examination
Hematologic,
chemical and
serologic studies
Renal biopsy Other
Crescentic Other
glomerulonephritis
Fig. 6. Algorithmic approach to diagnosis and therapy of patients with pulmonaty renal syndrome.
methyiprednisolone is $156. However, since the cost of dialysis is
about $20,000/year, it may be cost effective to use plasmapheresis
in all patients with a serum creatinine level < 5—6 mg/dl.
Appropriately conducted prospective trials obviously are required
[80]. I believe that the diagnostic and therapeutic approach
provided here represents a reasonable and cost-conscious regi-
men until parameters can be delineated that predict which
patients will develop the most aggressive GPS requiring the most
aggressive treatment, and what that treatment should be.
Questions and answers
DR. JOHN T. HARRINGTON (Dean ad interim, Tufts University
School of Medicine, Boston, Massachusetts): Why does anti-GBM
antibody cause disease in patients with "real" Goodpasture's
disease, whereas the same anti-GBM antibodies in the patient
with Alport's syndrome who has received a transplant do not eat
up the glomerular basement membrane?
DR. BOLTON: That is a terrific question. I do not know the
answer. The antibody specificity by immunoblot appears to be the
same. Whether the difference is related to transplant immunosup-
pression or different epitope specificities in the de-novo glomer-
ulonephritis is not known.
DR. AJAY SINGH (Division of Nephroloçy, New England Medical
Center, Boston): My first question is about the nature of the
antibody response in patients with Goodpasture's syndrome. As
you know, McPhaul et al, in their classic study [141, and others I'm
sure, have documented that IgG is the predominant isotype in
patients with Goodpasture's. However, I recall that some studies
also have suggested a unique subclass distribution among patients
with Goodpasture's syndrome as compared to sera from normal
1762 Nephrology Forum: Goodpasture's syndrome
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subjects. This would suggest a regulatory defect in the immune
response. Could you comment on this? Further, do you know of
studies that have explored whether certain idiotypes are more
frequently expressed in the anti-GBM antibody response?
DR. BOLTON: Segelmark examined antigen restriction and IgG
subclass of anti-GBM antibodies using purified monomers of a1,
a2, a3, and a4 chains. There was a preference for IgG 1 isotypes
in Goodpasture's syndrome but a subset, mostly females, also had
high-titer IgG 4 antibodies [18]. Lewis et al also have noted a
relative absence of IgG 3 isotype and anti-GBM disease and large
amounts of IgG 4, a pattern of distribution different from normal
serum components [81]. Rees et al have reviewed the clinical and
experimental data in great detail regarding idiotype responses and
immune regulation [23].
DR. SINGH: As you know, David Isenberg and Yehuda Shoen-
feld and others have reported the presence of certain idio-
types—in particular 16/6—shared among different patients with
lupus [82, 83]. Indeed, with respect to the 16/6 idiotype, Shoenfeld
has reported that when antibodies expressing this idiotype are
injected into normal laboratory mice, they develop disease [84].
Has this sort of work been performed in Goodpasture's syn-
drome?
DR. BOLTON: Several animal models have been used to study
these questions and are reviewed in the excellent chapter by Rees
that I mentioned [23].
DR. SINGH: My other question is directed towards the genetics
of Goodpasture's syndrome. A close association between DR2
and Goodpasture's syndrome has been reported in the literature
[15, 85]. However, as you know, the Goodpasture's antigen
(COL4A5) has been cloned, and maps to the q36 to q37 site on
chromosome 2 [86], whereas the HLA antigen, DR2, maps to
chromosome 6. These observations would suggest a nonstructural
explanation for the relationship of DR2 with Goodpasture's.
What do you think might be the association?
DR. BOLTON: T agree. Presumably immune responsiveness to the
Goodpasture's antigen is linked to the DR2, that is, peptide
processing and presentation to T-cell receptors.
DR. NIcoLAos E. MADIAS (Chief Divison of Nephrology, New
England Medical Center): My question concerns the Goodpas-
ture's epitope. Can you expand on what aspects of the nature and
suprastructure of Goodpasture's epitope might account for its
cryptic properties?
DR. BOLTON: The epitope being bound by Goodpasture's serum
is sequestered inside the hexamer, which is made up of the
globular regions of the various noncollagenous domains. One can
increase the binding between the noncollagenous domain and
Goodpasture's antibody up to 50-fold by revealing the epitope;
this can be done by treating the hexamer with acid which unfolds
it. Binding is also diminished by manipulations that affect tertiary
structure, such as reduction and alkylation, digestion with trypsin
and cyanogen bromide, and disruption of lysines by acetylation.
Thus, the antigen is cryptic or hidden and discontinuous.
DR. MIAs: Is the stoichiometry and assembly of the subunits
of the epitope identical at the various sites where Goodpasture's
epitope exists?
DR. BOLTON: I don't know. I suspect that it is not. Basement
membrane in the lung and kidney have different dimer/monomer
ratios for a3, with kidney being mostly dimers and some mono-
mer, but lung being mostly monomer and some dimer [87]. This
suggests that there are differences even though the amino acids
are the same.
DR. HARRINGTON: I have a followup question regarding the
same amino acid epitope but at a clinical level. Smoking, hair
spray, and other pulmonary toxins frequently are invoked as
stimuli to the production of Goodpasture's syndrome. If that is
true, why does it happen so extraordinarily infrequently?
DR. BOLTON: We are beginning to see a wide spectrum of
anti-GBM disease ranging from patients who are entirely asymp-
tomatic to those who have RPGN. It is not known why this
spectrum exists. It is probably related to the intensity of exposure
to the antigen, or to the epitopes involved, or to genetically
influenced immune responsiveness.
DR. ANDREW J. KING (Division of Nephrology, New England
Medical Center): Does Goodpasture's syndrome originate in the
kidney? If so, what is the sequence of events? Specifically, is there
release of collagen or some other process that initiates the
disease?
DR. BOLTON: We think that it must originate from kidneys, but
I do not know that anybody has really shown that. Ray Steblay
showed years ago that you can cause Goodpasture's syndrome in
animals by immunizing with lung basement membrane [88]. The
list of things that cause release of basement membrane constitu-
ents includes a wide range, from cortical necrosis to membranous
nephropathy to other underlying disease. There are all sorts of
insults in the kidney that have been associated with it. Not so in
the lungs. Maybe that points to the kidney as being the primary
site. But I don't know that for sure.
DR. KING: Frequently these patients present Friday evening in
the emergency room. We rely on ANCA and indirect immuno-
fluorescence as our guidelines as to whether the patient has this
type of disease. Why do you think the renal biopsy is essential in
the management of patients who are not dialysis dependent? Do
you ever rely on these serologic markers?
DR. BOLTON: In the situation that you describe, in which the
patient arrives at off hours, we go ahead and treat if we cannot get
the pathology. We use clinical judgment and give pulse methyl-
prednisolone and wait until we get the definitive answer. We use
the biopsy because of the inability of the clinical course to reveal
the degree of crescent formation and cellularity, and thus revers-
ibility of crescents, and the degree of fibrosis and scarring. If there
is severe sclerosis in the glomeruli or interstitium, I would tend to
be much less aggressive in terms of treatment and have a much
lower threshold for stopping.
DR. HARRINGTON: How do you treat the patient who is anti-
GBM positive? The data you showed revealed a strong correlation
between a serum creatinine of less than 5 mg/dl and a percentage
of crescents of less than 50%, and vice versa. In view of those data
and the low cost of measuring the serum creatinine, versus a renal
biopsy, why don't we believe the serum creatinine and act on it?
DR. B0LT0N: In today's cost-conscious environment, we might
be headed in this direction, I feel more secure in knowing how
much sclerosis is present to tell the patient what I think the
prognosis is going to be. I cannot tell the patient as much about
prognosis by looking at the serum creatinine.
DR. HARRINGTON: Do you mean that if the serum creatinine is
I or 6 mg/dl, you can't predict the outcome?
DR. BOLTON: As Figure 5 shows, histology is very accurate in
predicting prognosis. The numbers are too small for serum
creatinine <5 mg/dI and < 50% crescents to know whether serum
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creatinine alone is predictive. If the serum creatinine is > 6 mg/dl,
however, there is probably much less chance of the patient
responding.
DR. MADIAS: I would like to return to Dr. Harrington's question
about Alport's syndrome. As you mentioned, most cases of
X-linked Alport's syndrome have defects of the a5(IV) chain,
which can affect the cx3(IV) chain [89]. I would have expected that
most anti-GBM antibodies post grafting would be anti-5. Do the
few patients who develop aggressive anti-GBM disease have
predominantly anti-cs3 antibodies as opposed to anti-cs3, and is it
known whether their genetic defect is different? Is there a
relationship between aggressive anti-GBM disease and pre-exist-
ing rejection episodes? Under what circumstances should one
monitor levels of anti-GBM antibodies?
DR. BOLTON: In the one case examined, the de-novo antibodies
were to a3 and not a5 or other chains [44]. 1 am not aware of
analysis of genetic defects in those with and without de-novo
disease, but that is an interesting question. I am also not aware of
an association with previous rejection, but the numbers are very
small. I do not believe prospective monitoring of anti-GBM
antibodies is warranted.
DR. KING: Many of the patients who present to us are dialysis
dependent. Do we treat for possible pulmonary hemorrhage? Do
you believe in screening patients for pulmonary hemorrhage by
using carbon monoxide diffusion capacity and other modalities?
DR. BOLTON: We do not routinely do that. if the patient does
not have any kind of clinical pulmonary symptoms, we do not
screen or treat.
DR. SINGH: Work from Kalluri and colleagues presented in
abstract form at the recent American Society of Nephrology
meeting suggests that there is variable phenotypic expression of
anti-GBM disease in murine models [58]. In this regard, humans
also demonstrate phenotypic variability, from anti-GBM nephritis
without pulmonary abnormalities to the full-blown Goodpasture's
syndrome [3]. Could you comment on the potential role of genetic
factors in modulating the clinical expression of anti-GBM dis-
ease?
DR. BouroN: There are differences in the clinical phenotype
that occur based on the underlying immune response. This
response is very complex in terms of the type of cytokine response,
type and degree of antibody and cellular immune response, and
other effector systems. Presumably genetic influence in all these
effector systems dictates the final clinical expression.
DR. HARRINGTON: I don't understand the patients who are
double positive, that is, ANCA and anti-GBM positive. Is their
disease closer to Goodpasture's or Wegener's? Do they have
double disease or is this one disease? Does it make a difference in
clinical outcome whether they are P-ANCA versus C-ANCA
positive?
DR. BOLTON: I really do not know. A few years ago ANCA
positivity with anti-GBM disease was considered rare. Flowevcr,
now there are a number of papers indicating 30% association.
Most arc P-ANCA (75%) and titers of ANCA and anti-GBM
antibodies tend to be inversely related. I am not convinced that
ANCA causes disease, but it could. It is appealing to think that
these patients have vasculitis that damages the kidney, which
releases basement membrane and then secondary anti-GBM
antibodies are formed. I do not know whether these secondary
antibodies are pathogenic. Thus, some might be closer to Wege-
ner's, while others are more like Goodpasture's syndrome.
DR. MADIAS: Do any of these patients have evidence of systemic
vasculitis?
DR. B0L1oN: They have many vague manifestations suggestive
of vasculitis. Histologic lesions of vasculitis are uncommon, how-
ever.
DR. MAD!AS: About a year ago in a Nephrology Forum, Dr.
Robert Atkins discussed the role of cytokines, specifically IL-i, in
the pathogenesis of the entity and presented data on the beneficial
effects of the IL-l receptor antagonist (IL-Ira) in a rat model of
accelerated anti-GBM disease [90]. He concluded his Forum by
saying that he and his colleagues were setting up an international
multicenter trial to study the use of IL-ira as an adjunct to
conventional immunosuppression in patients with RPGN includ-
ing anti-GBM disease. Do you know whether this trial is in
progress?
DR. BOLTON: I talked to Bob at the meetings this past month.
He did not say anything about it going forward. I do not know
what the status is.
DR. MADtAS: You listed a number of futuristic therapies. Do
you think gene therapy will be included among them in an effort
to alter cytokine production?
DR. BOLTON: This is certainly possible, certainly futuristic, and
raises many questions. How do you target the gene to its site of
action? How do you control it? What are the long-term effects?
How does it perturb other regulatory processes? What are the
unexpected consequences? The leaps between theories, genes,
animal models, and the bedside are significant. Gene therapy is an
appealing approach to the control of inflammation, but from a
practical point we need much more information.
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